Clinical Trials Logo

Newly Diagnosed Glioblastoma clinical trials

View clinical trials related to Newly Diagnosed Glioblastoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05163080 Active, not recruiting - Clinical trials for Newly Diagnosed Glioblastoma

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

SURVIVE
Start date: November 18, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to determine whether adding SurVaxM to standard-of-care temozolomide chemotherapy is better than temozolomide treatment alone for patients with newly diagnosed glioblastoma. This study is designed to compare the length of survival in patients with newly diagnosed glioblastoma who receive temozolomide plus SurVaxM to that of patients treated with standard-of-care temozolomide plus placebo. This study aims to discover what effects, both good and bad, this combination of drugs may have on you and to see if the study drug (SurVaxM) can create an immune response in your blood that is directed against your cancer cells. This study also aims to determine whether treatment with SurVaxM plus temozolomide improves the survival of glioblastoma patients like yourself compared to treatment with temozolomide alone.

NCT ID: NCT04600817 Active, not recruiting - Clinical trials for Newly Diagnosed Glioblastoma

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Start date: December 31, 2020
Phase: Phase 2
Study type: Interventional

A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

NCT ID: NCT03899857 Active, not recruiting - Clinical trials for Newly Diagnosed Glioblastoma

Pembrolizumab for Newly Diagnosed Glioblastoma

PERGOLA
Start date: October 21, 2020
Phase: Phase 2
Study type: Interventional

The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.

NCT ID: NCT03782415 Active, not recruiting - Glioblastoma Clinical Trials

Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

Start date: December 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Part 1 is an open-label, single-arm, dose escalation study of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Evaluate safety and tolerability of ibudilast (MN-166) and TMZ combination treatment for 1 cycle (28 days); determine dosage in dose-finding study. Part 2 will evaluate efficacy of fixed-dose MN-166 (ibudilast) and TMZ combination treatment for 6 cycles (~6 months) until disease progression, unacceptable tolerability and/or toxicity or loss of life.

NCT ID: NCT03400917 Active, not recruiting - Clinical trials for Newly Diagnosed Glioblastoma

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma

Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label phase II clinical trial in which approximately 55 patients with newly diagnosed glioblastoma (GBM) will be enrolled with the intent to receive an autologous dendritic cell vaccine consisting of autologous dendritic cells loaded with autologous tumor-associated antigens (AV-GBM-1).